Celon Pharma SA (CLN) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.009x

Based on the latest financial reports, Celon Pharma SA (CLN) has a cash flow conversion efficiency ratio of -0.009x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-4.79 Million ≈ $-1.32 Million USD) by net assets (zł528.78 Million ≈ $145.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Celon Pharma SA for the company's overall valuation and market capitalisation.

Celon Pharma SA - Cash Flow Conversion Efficiency Trend (2012–2025)

This chart illustrates how Celon Pharma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Celon Pharma SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Celon Pharma SA ranked by their cash flow conversion efficiency. Explore how high is Celon Pharma SA's earnings quality to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Settlebank Corporation KQ:234340	0.049x
Kardan Israel Ltd TA:KRDI	-0.092x
EBEST Investment & Securities Co. Ltd KQ:078020	-0.086x
EMS Limited NSE:EMSLIMITED	-0.029x
Arman Financial Services Limited NSE:ARMANFIN	0.087x
W-SCOPE CHUNGJU PLANT LTD (PROPOSE KQ:393890	-0.024x
ITHAX Acquisition Corp III Class A Ordinary Shares NASDAQ:ITHA	27.020x
BAIC Motor Corp Ltd F:2B5	0.087x

Annual Cash Flow Conversion Efficiency for Celon Pharma SA (2012–2025)

The table below shows the annual cash flow conversion efficiency of Celon Pharma SA from 2012 to 2025. View CLN stock price and chart for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	zł382.99 Million ≈ $105.40 Million	zł23.86 Million ≈ $6.57 Million	0.062x	+344.66%
2024-12-31	zł445.21 Million ≈ $122.53 Million	zł-11.34 Million ≈ $-3.12 Million	-0.025x	-36.49%
2023-12-31	zł445.56 Million ≈ $122.62 Million	zł-8.31 Million ≈ $-2.29 Million	-0.019x	-90.39%
2022-12-31	zł479.65 Million ≈ $132.01 Million	zł-4.70 Million ≈ $-1.29 Million	-0.010x	-112.35%
2021-12-31	zł554.00 Million ≈ $152.47 Million	zł43.95 Million ≈ $12.10 Million	0.079x	-51.36%
2020-12-31	zł434.67 Million ≈ $119.63 Million	zł70.90 Million ≈ $19.51 Million	0.163x	+1537.33%
2019-12-31	zł445.04 Million ≈ $122.48 Million	zł-5.05 Million ≈ $-1.39 Million	-0.011x	-118.03%
2018-12-31	zł448.73 Million ≈ $123.50 Million	zł28.24 Million ≈ $7.77 Million	0.063x	+9.40%
2017-12-31	zł439.85 Million ≈ $121.05 Million	zł25.30 Million ≈ $6.96 Million	0.058x	+12.15%
2016-12-31	zł402.50 Million ≈ $110.77 Million	zł20.65 Million ≈ $5.68 Million	0.051x	-90.13%
2015-12-31	zł100.82 Million ≈ $27.75 Million	zł52.37 Million ≈ $14.41 Million	0.519x	+48.46%
2014-12-31	zł69.62 Million ≈ $19.16 Million	zł24.36 Million ≈ $6.70 Million	0.350x	+116.14%
2013-12-31	zł52.20 Million ≈ $14.37 Million	zł8.45 Million ≈ $2.33 Million	0.162x	-30.09%
2012-12-31	zł55.57 Million ≈ $15.29 Million	zł12.87 Million ≈ $3.54 Million	0.232x	--

About Celon Pharma SA

WAR:CLN Poland Drug Manufacturers - Specialty & Generic

Market Cap

$231.31 Million

zł840.49 Million PLN

Market Cap Rank

#16113 Global

#105 in Poland

Share Price

zł21.60

Change (1 day)

-2.48%

52-Week Range

zł18.82 - zł23.50

All Time High

zł51.09